Asia Will Become Strategic Imperative For Pharmaceutical Companies, Quintiles Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pipeline pressures will make Asia a contributor to drug discovery and research innovation as well as a market and support powerhouse, the CRO says.
You may also be interested in...
Beyond BRIC: 'Pharmerging' Markets Loom If Pharma Is To Expand, IMS Study Says
Drug makers need to more aggressively target so-called "pharmerging" markets - but not just the usual suspects. Brazil, Russia, India and China remain highly important, but in a March 16 report, IMS Health predicts that 17 countries, in total, will contribute 48 percent of annual market growth in 2013, up from 37 percent last year
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.